Cargando…

An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer

The phosphoinositide-3-kinase (PI3K) pathway is commonly deregulated in breast cancer through several mechanisms, including PIK3CA mutation and loss of phosphatase and tensin homolog (PTEN) and inositol polyphosphate 4-phosphatase-II (INPP4B). We aimed to evaluate the predictive relevance of these b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sueta, Aiko, Yamamoto, Yutaka, Yamamoto-Ibusuki, Mutsuko, Hayashi, Mitsuhiro, Takeshita, Takashi, Yamamoto, Satoko, Iwase, Hirotaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277449/ https://www.ncbi.nlm.nih.gov/pubmed/25542038 http://dx.doi.org/10.1371/journal.pone.0116054

Ejemplares similares

Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2015)

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2018)

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer
por: Fujiwara, Saori, et al.
Publicado: (2014)

Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence
por: Sueta, Aiko, et al.
Publicado: (2017)

Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy
por: Omoto, Yoko, et al.
Publicado: (2015)

Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer
por: Hayashi, Mitsuhiro, et al.
Publicado: (2015)

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2016)

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer
por: Suyama, Koichi, et al.
Publicado: (2017)

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer
por: Fujiki, Yoshitaka, et al.
Publicado: (2018)

Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary breast cancer
por: Tomiguchi, Mai, et al.
Publicado: (2016)

A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer
por: Yamamoto, Satoko, et al.
Publicado: (2013)

The role of exosomal microRNAs; focus on clinical applications in breast cancer
por: Sueta, Aiko, et al.
Publicado: (2019)

PTIP Associated protein 1, PA1, Is an Independent Prognostic Factor for Lymphnode Negative Breast Cancer
por: Takeshita, Takashi, et al.
Publicado: (2013)

A progressive and refractory case of breast cancer with Cowden syndrome
por: Sueta, Aiko, et al.
Publicado: (2022)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer
por: Shiota, Takuya, et al.
Publicado: (2016)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
por: Kosaka, Yoshimasa, et al.
Publicado: (2020)

A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character
por: Hayashi, Mitsuhiro, et al.
Publicado: (2013)

Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival
por: Rezano, Andri, et al.
Publicado: (2013)

High density of CD204‐positive macrophages predicts worse clinical prognosis in patients with breast cancer
por: Miyasato, Yuko, et al.
Publicado: (2017)

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
por: Cizkova, M, et al.
Publicado: (2013)

Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion
por: Okumura, Yasuhiro, et al.
Publicado: (2008)

PIK3CA and PTEN Genes Expressions in Breast Cancer
por: Alowiri, Nabil Hadi, et al.
Publicado: (2019)

The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients
por: Hayama, Shouko, et al.
Publicado: (2023)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung
por: Stjernström, Annika, et al.
Publicado: (2014)

Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases
por: Palimaru, Irina, et al.
Publicado: (2013)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
por: Shi, Qiyun, et al.
Publicado: (2022)

PIK3CA amplification and PTEN loss in diffused large B-cell lymphoma
por: Cui, Wenli, et al.
Publicado: (2017)

Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
por: Fiascarelli, Alessio, et al.
Publicado: (2023)

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project
por: Peixoto, Ana, et al.
Publicado: (2023)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
por: Patra, Satyajit, et al.
Publicado: (2017)

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
por: Dirican, Ebubekir
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gtf0vjmj9vo40r2557rmvnkdmc